Fibroblast growth factor 21 is associated with increased serum total antioxidant capacity and oxidized lipoproteins in humans with different stages of chronic kidney disease
| Autor: | López Estrada Angelina, Espinosa Cuevas Ángeles, Gómez Pérez Francisco J, Guillén Pineda Luz Elizabeth, Palacios Báez Lucía, Navarro Flores María Fernanda, Gómez Sámano Miguel Ángel, Rincón Pedrero Rodolfo, Zuarth Vázquez Julia María, Morales García Mariana Guadalupe, Martínez Sánchez Froylan David, López Cervantes Malaquías, Vargas Abonce Valerie Paola, Ramírez González Julia Berenice, Vera Zertuche Juan Mauricio, Baeza Arias Yolanda Victoria, Pacheco Domínguez Reyna Lizette, Correa Rotter Ricardo, Morales Buenrostro Luis E, Vega Vega Olynka, López Carrasco Guadalupe, Fonseca Correa Jorge Ignacio, Alberú Gómez Josefina, Mendoza de la Garza María de los Ángeles, Cuevas Ramos Daniel |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
FGF21 Endocrinology Diabetes and Metabolism Renal function fibroblast growth factor 21 030209 endocrinology & metabolism medicine.disease_cause Diseases of the endocrine glands. Clinical endocrinology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine oxidative stress Original Research 030304 developmental biology glomerular filtration rate 0303 health sciences business.industry medicine.disease RC648-665 serum total antioxidant capacity Antioxidant capacity Endocrinology business chronic kidney disease Oxidative stress Kidney disease |
| Zdroj: | Therapeutic Advances in Endocrinology and Metabolism, Vol 12 (2021) Therapeutic Advances in Endocrinology and Metabolism |
| ISSN: | 2042-0196 |
| Popis: | Background and aims: Oxidative stress (OS) induces the production of fibroblast growth factor 21 (FGF21). Previous data have revealed that FGF21 protects cells from OS injury and death, making it a potential therapeutic option for many diseases with increased OS. However, the association of this growth factor with OS markers in humans with chronic kidney disease (CKD) remains unknown. This study aims to evaluate the association of serum FGF21 with serum total antioxidant capacity (TAC) and oxidized low-density lipoproteins (OxLDL) in subjects in different stages of kidney disease. Methods: This is a cross-sectional study that included 382 subjects with different stages of CKD, irrespective of type 2 diabetes (T2D) diagnosis. Associations of serum FGF21 with OxLDL, TAC, sex, age, body mass index (BMI), fasting plasma glucose, estimated glomerular filtration rate (eGFR), T2D, and smoking, were evaluated through bivariate and partial correlation analyses. Independent associations of these variables with serum FGF21 were evaluated using multiple linear regression analysis. Results: Serum FGF21 was significantly and positively correlated with age ( r = 0.236), TAC (lnTAC) ( r = 0.217), and negatively correlated with eGFR ( r = −0.429) and male sex ( r = −0.102). After controlling by age, sex, BMI, T2D, smoking, and eGFR; both TAC and OxLDL were positively correlated with FGF21 ( r = 0.117 and 0.158 respectively, p Conclusion: A positive association between serum FGF21 and OS has been found independently of renal function in humans. Results from the present study provide novel information for deeper understanding of the role of FGF21 in OS in humans with CKD and T2D; mechanistic studies to explain the association of serum FGF21 with oxidative stress in CKD are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|